NasdaqGM - Delayed Quote USD

Theravance Biopharma, Inc. (TBPH)

9.12 -0.02 (-0.22%)
At close: April 26 at 4:00 PM EDT
8.88 -0.24 (-2.63%)
After hours: April 26 at 4:05 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
57,424.00
57,424.00
51,346.00
55,311.00
71,857.00
Gross Profit
--
--
--
--
71,857.00
Operating Expense
110,716.00
111,073.00
137,463.00
301,315.00
369,484.00
Operating Income
-53,292.00
-53,649.00
-86,117.00
-246,004.00
-297,627.00
Net Non Operating Interest Income Expense
6,766.00
6,766.00
2,176.00
-7,438.00
-4,106.00
Other Income Expense
-2,743.00
-2,386.00
-8,874.00
-11,780.00
-1,610.00
Pretax Income
-49,269.00
-49,269.00
-92,815.00
-265,222.00
-303,343.00
Tax Provision
5,924.00
5,924.00
9.00
-151.00
-8,520.00
Net Income Common Stockholders
-55,193.00
-55,193.00
872,132.00
-199,426.00
-278,017.00
Diluted NI Available to Com Stockholders
-55,193.00
-55,193.00
872,132.00
-199,426.00
-278,017.00
Basic EPS
-1.00
--
11.85
-2.87
-4.46
Diluted EPS
-1.00
--
11.85
-2.87
-4.46
Basic Average Shares
55,303.00
--
73,591.00
69,461.00
62,345.00
Diluted Average Shares
55,303.00
--
73,591.00
69,461.00
62,345.00
Total Operating Income as Reported
-56,035.00
-56,035.00
-91,957.00
-257,784.00
-297,627.00
Total Expenses
110,716.00
111,073.00
137,463.00
301,315.00
369,484.00
Net Income from Continuing & Discontinued Operation
-55,193.00
-55,193.00
872,132.00
-199,426.00
-278,017.00
Normalized Income
-53,026.03
-53,308.06
-85,813.54
-253,298.07
-294,823.00
Interest Income
9,116.00
9,116.00
8,545.00
1,109.00
4,441.00
Interest Expense
2,350.00
2,350.00
6,369.00
8,547.00
8,547.00
Net Interest Income
6,766.00
6,766.00
2,176.00
-7,438.00
-4,106.00
EBIT
-46,919.00
-46,919.00
-86,446.00
-256,675.00
-294,796.00
EBITDA
-46,919.00
-42,663.00
-79,422.00
-248,077.00
-287,824.00
Reconciled Depreciation
4,256.00
4,256.00
7,024.00
8,598.00
6,972.00
Net Income from Continuing Operation Net Minority Interest
-55,193.00
-55,193.00
-92,824.00
-265,071.00
-294,823.00
Total Unusual Items Excluding Goodwill
-2,743.00
-2,386.00
-8,874.00
-11,780.00
--
Total Unusual Items
-2,743.00
-2,386.00
-8,874.00
-11,780.00
--
Normalized EBITDA
-44,176.00
-40,277.00
-70,548.00
-236,297.00
-287,824.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-576.03
-501.06
-1,863.54
-7.07
--
12/31/2020 - 5/16/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SYBX Synlogic, Inc.
1.8700
-1.06%
 
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%
 
PRTC PureTech Health plc
28.50
+2.24%
 
KALV KalVista Pharmaceuticals, Inc.
10.78
+2.76%
 
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
 
SPRO Spero Therapeutics, Inc.
1.4600
+2.10%
 
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
 
ZA8.BE Zymeworks Inc
7.70
+1.32%
 
RPHM Reneo Pharmaceuticals, Inc.
1.6700
+1.21%
 
XNCR Xencor, Inc.
19.98
+3.90%